Industry

Elegrobart reduces proptosis in active thyroid eye disease

Healio Ophthalmology2d ago1 min read

A subcutaneous monoclonal antibody induced greater reductions in proptosis at 24 weeks than placebo for people with active thyroid eye disease, according to topline results from the REVEAL-1 trial.Elegrobart (Viridian Therapeutics) is a half-life extended monoclonal antibody designed to target the insulin-like growth I receptor. In the phase 3 REVEAL-1 trial, researchers assessed the efficacy of the therapy among 132 patients with active thyroid eye disease. Participants were randomly assigned to elegrobart every 4 weeks, elegrobart every 8 weeks or placebo. The primary outcome was proptosis

Read full article on Healio Ophthalmology

AI Summary

Quick Take

Topline Phase 3 results from the REVEAL-1 trial show that elegrobart, a subcutaneous IGF-1R monoclonal antibody, significantly reduced proptosis in patients with active thyroid eye disease compared to placebo at 24 weeks. Developed by Viridian Therapeutics, the therapy utilizes a half-life extended design to allow for less frequent subcutaneous dosing.

Why It Matters

The current standard for IGF-1R inhibition in thyroid eye disease requires intravenous infusions, which can be burdensome for both patients and clinical staff. Elegrobart’s subcutaneous delivery and extended half-life could shift the treatment paradigm toward a more convenient, office-based injection model. If these results hold, it may offer a competitive alternative to teprotumumab with potentially fewer logistical hurdles and a reduced treatment burden for those in the active phase of the disease.

Key Findings

Elegrobart achieved a statistically significant reduction in proptosis at 24 weeks compared to placebo in patients with active thyroid eye disease.
The trial evaluated two different subcutaneous dosing regimens: administration every four weeks and every eight weeks.
The study specifically targeted the insulin-like growth I receptor (IGF-1R), a validated pathway for reducing the orbital inflammation and tissue remodeling associated with TED.
The REVEAL-1 trial enrolled 132 participants, providing a robust sample size for a Phase 3 assessment of this orphan disease population.

Study Snapshot

Design

Phase 3, randomized, placebo-controlled trial (REVEAL-1)

Population

Patients with active thyroid eye disease

Sample Size

132 patients

Practice Implications

Clinicians should prepare for a potential shift in TED management from IV infusion centers to subcutaneous administration in the clinic. The efficacy seen in both the 4-week and 8-week dosing arms suggests that elegrobart could provide flexibility in managing patient response and treatment adherence.

Who's Affected

Oculoplastic SurgeonsNeuro-ophthalmologistsEndocrinologistsComprehensive Ophthalmologists

What's Next

Following these topline results, the industry will look for more detailed data on secondary endpoints such as diplopia improvement and Clinical Activity Score (CAS). These findings will likely form the basis for future regulatory submissions and potential FDA approval.

Evidence StrengthStrong

AI-generated summary — always read the original source for full context

Discussion

No comments yet. Be the first to share your thoughts.